

CORPORATE OVERVIEW


Innovation Leader

Selexis SA, a JSR Life Science Company, is the global leader in mammalian cell line development with best-in-class modular technology and highly specialized solutions that enable the life science industry to rapidly develop and commercialize innovative biotherapeutics and vaccines.

Our global partners are utilizing Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company's technologies shorten development timelines and reduce manufacturing risks.

Delivering Results

The Selexis approach to cell line development and protein expression has already generated one of the most impressive portfolios of clinical and commercial cell lines producing a broad range of biotherapeutics from biosimilars to difficult-to-express proteins.¹⁻⁵



Redefining Best-in-Class Cell Line Development Technology

Selexis' innovation and expertise have driven the development and ongoing optimization of the most robust and flexible cell line-based protein expression platform in the industry — the SUREtechnology Platform™.

1. SUREtechnology Platform Partner pipeline as of August 9, 2022
2. "Cell Line Development Market Size, Regional Analysis, Competitive Market Share & Forecast, 2023", Global Market Insights
3. "Cell Line Development Market Analysis and Segment Forecasts 20 20202", Grandview Research
4. Internal research
5. Data from third-party disclosures

AT A GLANCE

STRONG PATENT PORTFOLIO

210+ granted

Selexis is the top cell line development firm for number of technology advancements.¹⁻³

HEADQUARTERS

Selexis SA

Stellar — Route de la Galaise, 36
1228 Plan-les-Ouates, Switzerland
+41 (0)22 308 93 60

LEADERSHIP TEAM

Mark W. Womack

Chief Executive Officer

Alberto Garotti

Senior Vice President
Site Head Geneva

Regine Brokamp

Chief Operating Officer

Roland Hecht, PhD

Chief Business Officer

**Best Medium
Workplaces™**

**Great
Place
To
Work.**

SWITZERLAND
2022

The SUREtechnology Platform™



Selexis SURE CHO-M Cell Line™ (CHO-K1)

The Selexis SURE CHO-M is a proprietary high performance cell line derived from CHO-K1 cells used for the production of biotherapeutics. Its growth and production properties have been well defined, and its feed strategy has been optimized for off-the-shelf media, allowing faster and more efficient scale-up to bioreactors.



SURE CHO-Mplus Libraries™

SURE CHO-Mplus Libraries represent a powerful and holistic approach to de-risk expression and production issues of difficult-to-express recombinant proteins. Indeed, they help reduce attrition rates in biotherapeutics development.



Selexis SGE® (Selexis Genetic Elements)

Selexis SGEs® are epigenetic DNA-based elements that control the dynamic organization of chromatin in all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis SGEs® can be used across a wide range of mammalian cell lines.



Selexis Proprietary Bioinformatics Tools

Selexis SUREscan®, SUREsignature™, and SUREclone™ are Selexis proprietary bioinformatic tools. Developed based on whole-genome sequencing data, they allow to respectively identify transgene-genome junctions, copy numbers and characterization, as well as clonality assessment.

Our Commitment

Productivity

Based on its capabilities and expertise, Selexis has been able to rescue promising products that client companies could not express at commercially viable levels. For example, with its proprietary CHO-M cell line, Selexis has already been able to reach bispecific titers up to 10g/L in bioreactor.

Versatility/Transferability

Selexis is able to transfer research cell banks (RCBs), culture maintenance conditions and scale up process to any manufacturer, giving our partners the choice for their CDMO. However, Selexis' preferred CDMO is KBI Biopharma. Together, Selexis and KBI Biopharma have successfully run more than 65 Selexis-KBI Integrated (SKI) programs, achieving high titers in accelerated timelines.

De-Risk Regulatory Issues

Selexis provide its partners with ICH-compliant documentation, proof of monoclonality and proven stability without compromising quality, speed and high productivity.

Our Mission

Continually provide breakthrough technologies to fundamentally improve the development and manufacture of biotherapeutics, improving patients quality of life.

BUSINESS INQUIRIES

Sonja Delalu, PhD EMEA

Director, Business Development and Licensing
sonja.delalu@selexis.com

Elodie Pothin, PhD EMEA

Manager, Business Development and Licensing
elodie.pothin@selexis.com

Jonathan Viola, PhD North America

Manager, Business Development and Licensing
jonathan.viola@selexis.com

Toshihiro Ogawa Asia

Senior Director, Business Development
togawa@kbibiopharma.com

